Literature DB >> 7651358

KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.

K Shibata1, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa, G Tsujimoto.   

Abstract

alpha 1-Adrenoceptors (ARs) comprise a heterogeneous family, and subtype-selective ligands are valuable for studying the functional role of each receptor subtype. We characterized a newly synthesized, alpha 1-AR antagonist, KMD-3213, by using Chinese hamster ovary cells stably expressing the three cloned human alpha 1-ARs (alpha 1a, alpha 1b, and alpha 1d), as well as native rat and human tissues. KMD-3213 potently inhibited 2-[2-(4-hydroxy-3-[125I]iodophenyl)ethylaminomethyl]-alpha-tetralone binding to the cloned human alpha 1a-AR, with a Ki value of 0.036 nM, but had 583- and 56-fold lower potency at the alpha 1b- and alpha 1d-ARs, respectively. KMD-3213 inhibited norepinephrine-induced increases in intracellular Ca2+ concentrations in alpha 1a-AR-expressing Chinese hamster ovary cells with an IC50 of 0.32 nM but had a much weaker inhibitory effect on the alpha 1b- and alpha 1d-ARs. Using pharmacologically well characterized native rat tissues [submaxillary gland (alpha 1A-AR-expressing tissue), liver (alpha 1B-AR-expressing tissue), and heart (mixed alpha 1A- and alpha 1B-AR-expressing tissue)], binding studies showed that inhibition curves for KMD-3213 in submaxillary gland and liver best fit a one-site model (with Ki values of 0.15 and 16 nM, respectively), whereas KMD-3213 had high and low affinity sites in heart membranes. Chloroethylclonidine treatment of rat heart membranes completely eliminated the low affinity sites for KMD-3213. Furthermore, in human liver and prostate KMD-3213 could identify high and low affinity sites, the Ki values of which corresponded well to those for the cloned human alpha 1a- and alpha 1b-ARs, respectively. Moreover, the affinity of KMD-3213 was found to be approximately 10-fold higher at the cloned human alpha 1a-AR than at the cloned rat alpha 1a-AR. KMD-3213 is a potent and highly selective antagonist for the human alpha 1a-AR and would be useful for studying the physiological roles of human alpha 1-AR subtypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651358

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  48 in total

1.  Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

Authors:  S Murata; T Taniguchi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  The role of several alpha(1)- and alpha(2)-adrenoceptor subtypes mediating vasoconstriction in the canine external carotid circulation.

Authors:  E W Willems; L F Valdivia; P R Saxena; C M Villalón
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

3.  Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes.

Authors:  Fumiko Suzuki; Takanobu Taniguchi; Seigo Nakamura; Yoshio Akagi; Chikara Kubota; Makoto Satoh; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

4.  Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

5.  Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice.

Authors:  Chihiro Hosoda; Akito Tanoue; Mari Shibano; Yoshio Tanaka; Masami Hiroyama; Taka-aki Koshimizu; Susanna Cotecchia; Tadaichi Kitamura; Gozoh Tsujimoto; Katsuo Koike
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

6.  Adrenergic receptors modulate motoneuron excitability, sensory synaptic transmission and muscle spasms after chronic spinal cord injury.

Authors:  M M Rank; K C Murray; M J Stephens; J D'Amico; M A Gorassini; D J Bennett
Journal:  J Neurophysiol       Date:  2010-11-03       Impact factor: 2.714

7.  Evaluation of alpha1-adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA.

Authors:  S Nakamura; T Taniguchi; F Suzuki; Y Akagi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 8.  α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.

Authors:  Shizuo Yamada; Yoshihiko Ito; Hideo Tsukada
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

9.  Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions.

Authors:  Hao Sun; Chad Moore; Patrick M Dansette; Santosh Kumar; James R Halpert; Garold S Yost
Journal:  Drug Metab Dispos       Date:  2008-12-12       Impact factor: 3.922

10.  Selective α1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity.

Authors:  Osamu Yokoyama; Hideaki Ito; Yoshitaka Aoki; Nobuyuki Oyama; Yoshiji Miwa; Hironobu Akino
Journal:  World J Urol       Date:  2009-10-16       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.